WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in ...

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...